Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Epitalon crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 222 certificate records for Epitalon products, from 70 vendors 131 reference a report on the testing laboratory's own system · 111 have a laboratory lookup that answered when last checked · 200 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Longevity research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

Epithalon

Signal depth

Low

No FDA label signal · 0 trials · 120 PubMed results

Preclinical

Research evidence

Current evidence for Epitalon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Epitalon has no clinical trials that name it and 120 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

Established

Mechanisms of Ageing and Development · 41 citations Effect of epitalon on the lifespan increase in Drosophila melanogaster International Journal of Cancer · 32 citations Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER‐2/neu transgenic mice Molecules · 31 citations AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism Journal Article Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Journal Article LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma. Journal Article Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-05 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What epitalon is

Epitalon is a short synthetic peptide that appears frequently in longevity and anti-aging discussions, especially in communities focused on speculative cellular-aging interventions.

Why it matters

This category draws heavy interest but often has weak labeling discipline. Epitalon is useful as a profile because it lets us represent the anti-aging bucket without pretending that the category has the same regulatory footing as approved metabolic drugs.

Regulatory context

Epitalon is not an FDA-approved anti-aging medicine in the United States. It belongs firmly in the research-market conversation.

Practical reading note

The phrase “anti-aging peptide” is usually more marketing category than medical category. Profiles like this should be read with extra skepticism around mechanism-to-outcome claims.